Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies targeting the EGF receptor (EGFR) tyrosine kinase, such as cetuximab and panitumumab, achieve clinically meaningful responses in patients affected by head and neck and colorectal cancers. Despite this evidence of efficacy, no genomic abnormalities that robustly predict sensitivity to EGFR blockade have been yet identified. This suggests that, in some tumor contexts, EGFR dependency is not acquired during neoplastic transformation and rather reflects an aberrant declination of physiologic traits typical of normal tissue counterparts. Indeed, EGFR signals are crucial for the reconstitution of damaged mucosa in the context of acute inflammation, and their sustained activation is likely to turn into a pro-oncogenic cue during chronic inflammation. Although positive predictors of response to anti-EGFR antibodies remain unknown, multiple determinants of resistance have been described, including alterations interfering with antibody–receptor interaction, deregulation of parallel signaling pathways, and mutations in downstream transducers. These findings provide new opportunities for the optimization of therapeutic strategies based on drug combinations. However, the emerging notion that genetic interactions and compensatory mechanisms may affect—both positively and negatively—the efficacy of targeted therapies complicates the rational design of combinatorial approaches and implies a rethinking of the criteria required to prioritize laboratory findings for clinical validation in investigational trials. Clin Cancer Res; 21(15); 3377–83. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“In line with the concept of oncogene addiction, response to EGFR inhibitors in NSCLC is strongly associated with the presence of activating mutations in the target gene (13).”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“In linewith the assumption that cancer is awound that never heals (20), it is likely that the upregulation of EGFR activity— normally involved in tissue repair in the context of acute inflammation—is turned into a pro-oncogenic cue during chronic inflammation.”
BackgroundEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · cited 1×
“The most frequent cause of resistance to first-generation small molecules targeting EGFR in NSCLC is amutation inEGFR (T790M),which reduces the affinity between the ATP-binding domain of the kinase and the inhibitor, impairing the ATP-competitive activity of the drug (31, 32).”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“Results of randomized phase III studies on chemorefractory metastatic colorectal cancers treated with cetuximab or panitumumab monotherapy led to the limitation in the use of anti-EGFR antibodies, together with chemotherapy, to patients bearing KRAS wild-type tumors (50).”
BackgroundPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Cited by
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
“Although CRC patients’ initial responses to surgical debulking and chemotherapy is often effective, relapse with drug-resistant cancer usually occurs and patients succumb to disease (Bertotti and Sassi, 2015; Jemal et al., 2009).”
BackgroundTesta, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
“Multiple mechanisms are responsible for primary or acquired resistance to EGFR blocking therapy, related to three different mechanisms: (i) reduced antibody-receptor interaction; (ii) activation of parallel substitute pathways; and (iii) constitutive activation of downstream signaling pathways (related to the presence…”
BackgroundRethink of EGFR in Cancer With Its Kinase Independent Function on Board
Thomas, R., & Weihua, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00800 · Cited by 201
“Nevertheless, secondary mutations in the extracellular domain of EGFR, mutations in KRAS, NRAS and C-Met, loss of PTEN and activating mutations in PIK3CA, and gain-of-activity in the IGFR pathway have been associated with acquired resistances of some cases of colorectal cancer (8, 9, 126, 127).”
BackgroundTumor heterogeneity: preclinical models, emerging technologies, and future applications
Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., & Gilardi, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1164535 · Cited by 172
Grugan, K. D., Dorn, K., Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Laquerre, S., Moores, S. L., & Chiu, M. L. (2017) · mAbs · doi:10.1080/19420862.2016.1249079 · Cited by 86
“Representative data from 3 replicate experiments for each target cell line is shown. subtype of NSCLC. JNJ-61186372 has been uniquely designed to target both EGFR and c-Met on NSCLC cells through multiple mechanism of action including signaling inhibition of both pathways and activation of Fc effector cells through th…”
BackgroundInfluential
Metadata
- Authors
- Bertotti, A., & Sassi, F.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Candiolo Cancer Institute (IT)
- Venue
- Clinical Cancer Research
- Published
- 2015-08-01
- Volume
- 21
- Issue
- 15
- Pages
- 3377-3383
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1919718700
- Cited by
- 45
- References
- 63
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 2 · 2016: 7 · 2015: 2
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- EGFR, anti-EGFR monoclonal antibody, cetuximab, panitumumab, drug resistance, predictive biomarkers, head and neck cancer, colorectal cancer, chronic inflammation, compensatory signaling pathways, combination therapy, targeted therapy
- MeSH terms
- Antibodies, Anti-Idiotypic, Head and Neck Neoplasms, Humans, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0848
- The paper
- Bertotti, A., & Sassi, F. (2015). Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.